A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C. diff) guided by the principles of ...

A new study published today in the American Journal of Infection Control (AJIC) suggests that allowing bedside nurses to independently order testing for C. difficile significantly decreased the amount ...

By: Staff Monday, October 7th, 2013 Researchers examined C. diff rates among hospitals in the Duke Infection Control Outreach Network before and after a switch from nonmolecular testing to polymerase ...

Arlington, Va., May 11, 2023 – A new study published today in the American Journal of Infection Control (AJIC) suggests that allowing bedside nurses to independently order testing for C. difficile ...

Arlington, Va. — June 27, 2024 — A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C.

After piloting new Clostridioides difficile guidelines for nine months, Memorial Healthcare System reduced unnecessary treatments by 20.1%, according to a study published June 27 in the American ...

The CDC provides a free online video for healthcare providers on testing for Clostridium difficile. In the video, Dr. Carolyn Gould, a medical epidemiologist in the Division of Healthcare Quality ...

After the first year of interventions at Emory Saint Joseph's Hospital, there was a 63% decrease in hospital-onset C. diff cases as compared to the two years prior. Through a series of interventions ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin during ...

Testing for Clostridium difficile infection is significantly lower than expected during diagnosis of inflammatory bowel disease, according to a study in Inflammatory Bowel Diseases, the official ...

Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...